Charlottesville, Virginia, United States The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Charlottesville.
The high activity for fund was in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. The fund is generally included in 2-6 deals every year.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biotechnology, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Candel, Landos Biopharma, ArcherDX. The fund has exact preference in a number of founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the PBM Capital Group, startups are often financed by The Peierls Foundation, Perceptive Advisors, National Securities Corporation. The meaningful sponsors for the fund in investment in the same round are Perceptive Advisors, Longwood Founders Fund, Boulder Ventures. In the next rounds fund is usually obtained by The Peierls Foundation, Sands Capital Ventures, Perceptive Advisors.
Related Funds
| Fund Name | Location |
| Altran | France, Ile-de-France, Neuilly-sur-seine |
| Applied Research Council | China, Hong Kong, Hong Kong Island |
| BankDhofar | Muscat, Muscat, Oman |
| Bartlit Beck Herman Palenchar & Scott | Chicago, Illinois, United States |
| Bild Alternative Investments Corporation | Canada, Markham, Ontario |
| Bryant Park Capital | New York, New York, United States |
| CresVentures | Lahore, Pakistan, Punjab |
| DIC | Japan, Shizuoka, Shizuoka Prefecture |
| EVC Thirty One Holdings | - |
| Firlej Kastory | Mazowieckie, Poland, Warsaw |
| Foreign Investment Promotion Board | - |
| Fujian Huamin Industry Group | China, Foochow, Fujian |
| InnoBio | Malaysia, Negeri Sembilan, Nilai |
| MRCF Biomedical Translation Fund | - |
| Quantum Pacific Capital | China, Hong Kong, Hong Kong Island |
| Rite Ventures | Stockholm, Stockholm County, Sweden |
| Sony Startup Acceleration Program | Lund, Skane Lan, Sweden |
| The Bank of Okinawa | Japan, Okinawa, Okinawa Prefecture |
| Transference Fund | China, Shanghai |
| Trifecta Capital | California, San Francisco, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
LEXEO Therapeutics | $100M | 09 Sep 2021 | New York, New York, United States | ||
Xalud Therapeutics | $30M | 24 Aug 2021 | New York, New York, United States | ||
SalioGen Therapeutics | $20M | 18 Feb 2021 | Burlington, Massachusetts, United States | ||
LEXEO Therapeutics | $85M | 07 Jan 2021 | New York, United States | ||
Acumen Pharmaceuticals | $75M | 20 Nov 2020 | California, United States | ||
Taysha Gene Therapies | $95M | 05 Aug 2020 | Dallas, Texas, United States | ||
Taysha Gene Therapies | $30M | 29 Apr 2020 | Dallas, Texas, United States | ||
Atsena Therapeutics | $8M | 01 Apr 2020 | Durham, North Carolina, United States | ||
ArcherDX | $55M | 17 Dec 2019 | Boulder, Colorado, United States |
– GenapSys is a company developing a highly accurate and scalable electronic sequencing platform.
– The company raised $70m in Series D equity financing.
– The investors in the round included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors.
– The proceeds from this financing will be used to continue advancing GenapSys’ semiconductor based next-generation sequencing (NGS) platform.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
LEXEO Therapeutics | $100M | 09 Sep 2021 | New York, New York, United States | ||
Xalud Therapeutics | $30M | 24 Aug 2021 | New York, New York, United States | ||
SalioGen Therapeutics | $20M | 18 Feb 2021 | Burlington, Massachusetts, United States | ||
LEXEO Therapeutics | $85M | 07 Jan 2021 | New York, United States | ||
Acumen Pharmaceuticals | $75M | 20 Nov 2020 | California, United States | ||
Taysha Gene Therapies | $95M | 05 Aug 2020 | Dallas, Texas, United States | ||
Taysha Gene Therapies | $30M | 29 Apr 2020 | Dallas, Texas, United States | ||
Atsena Therapeutics | $8M | 01 Apr 2020 | Durham, North Carolina, United States | ||
ArcherDX | $55M | 17 Dec 2019 | Boulder, Colorado, United States |
